Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reolysin and Carfilzomib in Relapsed/Refractory Multiple Myeloma
NCT02101944Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- May 2021
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelareorep in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoints: Number and severity of adverse events, Maximum tolerated dose of combination carfilzomib and wild-type reovirus up to 28 days and 2 more. Started Dec 2014; status: completed.
02
Drugs
pelareorep
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02101944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101944.